5 月 21 日,NMPA 官网显示,诺诚健华 CD19 单抗坦昔妥单抗(Tafasitamab)获批上市,用于联合来那度胺治疗不适合自体干细胞移植条件的复发/难治弥漫性大 B 细胞淋巴瘤(DLBCL)成人患者。此前该适应症曾被纳入优先审评。截图来源:NMPA 官网坦昔妥单抗是靶向 CD19 的人源化单克隆抗体,包含 Xencor 公司独有的工程化 Fc 结构域,显著强化了抗体依赖性细胞介导的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.